On May 31, 2021 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) reported that the publication of the 1st quarter 2021 financial results, which had been scheduled for June 1, 2021, will be postponed until June 25, 2021 (Press release, Vivoryon Therapeutics, MAY 31, 2021, View Source [SID1234583296]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In accordance with the decree of May 27, 2021 on amending some expiry dates of legal provisions made in connection with the COVID-19 outbreak as published on May 31, 2021, the Temporary COVID-19 Justice and Safety Act (Tijdelijke wet COVID-19 Justitie en Veiligheid) (the COVID Act) has been extended. Therefore, the annual general meeting will be held on Monday, June 28, 2021, at 10:30 a.m. (CEST) as a virtual meeting via an audio webcast which will be available, along with all relevant documents, on the company’s website at: View Source As there will be no physical meeting, it will not be possible to attend the meeting in person..